← Back to headlines
Biogen Acquires China Rights for Immune Disease Drug in $850M Deal
Biogen has announced plans to purchase the rights to an immune disease drug for the Chinese market. The deal is valued at up to $850 million.
20 Apr, 16:04 — 20 Apr, 16:04
Sources
Showing 1 of 1 sources
